Home
Home » companies

Anadys

3 Reasons Hep C Premiums Might Not Last

3 Reasons Hep C Premiums Might Not Last
Motley Fool

Roche: New Era Of Hepatitis Therapies Creates Short-Term Threat, Long-Term Opportunity

Roche: New Era Of Hepatitis Therapies Creates Short-Term Threat, Long-Term Opportunity
Seeking Alpha

Anadys acquisition sign of more to come

Anadys acquisition sign of more to come
The Deal

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market
TheStreet.com

Swiss pharma giant Roche to buy US-based hepatitis C specialist Anadys for $230 million

Swiss pharma giant Roche to buy US-based hepatitis C specialist Anadys for $230 million
Yahoo/AP

Hep C Drug Updates: Vertex and Anadys

Hep C Drug Updates: Vertex and Anadys
TheStreet.com

12 Cancer Stocks Being Snapped Up by Insiders

12 Cancer Stocks Being Snapped Up by Insiders
Seeking Alpha

News

ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Yahoo/PR NewsWire

News

15 Biotech Stocks With the Lowest Put/Call Ratios
Seeking Alpha
»

News

Anadys mulls strategic options on hepatitis C drug
Yahoo/AP
»